Related references
Note: Only part of the references are listed.Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Wassim Abida et al.
CLINICAL CANCER RESEARCH (2020)
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo et al.
LANCET ONCOLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C. Parker et al.
ANNALS OF ONCOLOGY (2020)
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Veda N. Giri et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
W Abida et al.
ANNALS OF ONCOLOGY (2019)
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
Zafeiris Zafeiriou et al.
EUROPEAN UROLOGY (2019)
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
Emmanuel S. Antonarakis et al.
EUROPEAN UROLOGY (2018)
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
Joaquin Mateo et al.
EUROPEAN UROLOGY (2018)
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer
Matti Annala et al.
EUROPEAN UROLOGY (2017)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2017)
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer
Mark M. Pomerantz et al.
CANCER (2017)
Human Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences
Lawrence A. Loeb
CANCER RESEARCH (2016)
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
Heather H. Cheng et al.
EUROPEAN UROLOGY (2016)
Familial Risk and Heritability of Cancer Among Twins in Nordic Countries
Lorelei A. Mucci et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
C. C. Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S. Gillessen et al.
ANNALS OF ONCOLOGY (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer (vol 161, pg 1215, 2015)
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Elizabeth K. Bancroft et al.
EUROPEAN UROLOGY (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
The genetic epidemiology of prostate cancer and its clinical implications
Rosalind Eeles et al.
NATURE REVIEWS UROLOGY (2014)
Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
Felix Dietlein et al.
TRENDS IN GENETICS (2014)
Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response
H. Christian Reinhardt et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
The p53 network: cellular and systemic DNA damage responses in aging and cancer
H. Christian Reinhardt et al.
TRENDS IN GENETICS (2012)
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Rohini Roy et al.
NATURE REVIEWS CANCER (2012)
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
Z. Kote-Jarai et al.
BRITISH JOURNAL OF CANCER (2011)
Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Da Yang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
Tomasz Byrski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The DNA-damage response in human biology and disease
Stephen P. Jackson et al.
NATURE (2009)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Share Paper
